NLRP3 and melanoma: Lee et al. introduce celastrol, as an inhibitor of NLRP3 infammasome, to reduce the potency of macrophages to stimulate migration and invasion of melanoma cells, which provide a novel anti-cancer strategy to modulate tumor microenvironment by suppressing NLRP3 infammasome and consequently reducing IL-1β production (Lee et al., 2019).